EUVIMEDEUVIMED entdecken
Systematische ÜbersichtNetzwerk-MetaanalyseOpen Access · CC BY-NC 4.0

Divergent Renal Benefits of Sodium-Glucose Cotransporter-2 Inhibitors and Mineralocorticoid Receptor Antagonists in Nondiabetic Kidney Disease

Rulong Chen, Jinxin Zhang, Jiating Chen, Tingfei Xie, Yunpeng Xu, Zhaoyong Hu, Jihong Chen

Kidney and Blood Pressure Research · 24.04.2026 · 51 (1) · 409-420

DOI: 10.1159/000552201 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Kidney and Blood Pressure Research, online erschienen am 24.04.2026. Verfasst von Rulong Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, The People's Hospital of Baoan Shenzhen, The Second Affiliated Hospital of Shenzhen University, Shenzhen Hospital of Guangd…. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Mineralocorticoid Receptor Antagonists, Kidney Diseases. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Nondiabetic kidney disease (NDKD) is a major contributor to chronic kidney disease worldwide. Although renin-angiotensin system inhibitors (RASi) remain standard therapy, sodium-glucose cotransporter-2 inhibitors (SGLT2i), non-steroidal mineralocorticoid receptor antagonists (non-steroidal MRAs), and glucagon-like peptide-1 receptor agonists are now recommended in clinical guidelines. However, direct comparative evidence to guide their prioritization in NDKD is limited.

Methods

We performed a systematic review and Bayesian network meta-analysis of randomized controlled trials enrolling adults with NDKD. The primary endpoint was the annualized change in estimated glomerular filtration rate (eGFR) slope; secondary endpoints included urine protein-to-creatinine ratio (UPCR), blood pressure, and biochemical safety parameters.

Results

Eighteen trials were included. SGLT2i, as add-on to RASi, produced the greatest preservation of kidney function compared with RASi alone (mean difference [MD] 12.1 mL/min/1.73 m2/year; 95% credible interval [CrI] 3.9 to 20.4). Non-steroidal MRA achieved the largest reduction in proteinuria versus RASi (UPCR MD −0.4 g/g; 95% CrI: −1.0 to −0.2). SGLT2i also yielded the greatest systolic blood pressure reduction versus RASi (MD −9.1 mm Hg vs. RASi; 95% CrI: −11.7 to −6.5). Surface-under-the-cumulative-ranking probabilities identified SGLT2i as most effective for eGFR slope preservation (99.8%) and non-steroidal MRA as most effective for proteinuria reduction (98.8%). Safety analyses showed a mild, expected hemoglobin decrease with SGLT2i and a nonsignificant creatinine rise with non-steroidal MRA.

Conclusions

SGLT2i and non-steroidal MRA confer distinct renal benefits in NDKD – SGLT2i primarily preserve kidney function, whereas non-steroidal MRAs most effectively reduce proteinuria. These results support a phenotype-driven therapeutic framework and highlight the need for head-to-head trials to validate precision-guided treatment strategies in NDKD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsMineralocorticoid Receptor AntagonistsKidney DiseasesHumansKidneyGlomerular Filtration Rate

Stichwörter der Autor:innen

Glucagon-like peptide-1 receptor agonistsNon-steroidal mineralocorticoid receptor antagonistsNondiabetic kidney diseaseRenin-angiotensin system inhibitorsSodium-glucose cotransporter-2 inhibitors

Substanzen

Sodium-Glucose Transporter 2 InhibitorsMineralocorticoid Receptor Antagonists

Autor:innen und Institutionen

  • Department of Nephrology, The People's Hospital of Baoan Shenzhen, The Second Affiliated Hospital of Shenzhen University, Shenzhen Hospital of Guangdong Provincial People's Hospital, The Affiliated Baoan Hospital of Sou…
  • Guangdong Key Laboratory of Nanomedicine, CAS-HK Joint Lab of Biomaterials, CAS Key Laboratory of Biomedical Imaging Science and System, Shenzhen Engineering Laboratory of Nanomedicine and Nanoformulations, CAS Key Lab…
  • Nephrology Division, Baylor College of Medicine, Huston, Texas, USA.

Zitieren

APA

Chen, R., Zhang, J., Chen, J., Xie, T., Xu, Y., Hu, Z., & Chen, J. (2026). Divergent Renal Benefits of Sodium-Glucose Cotransporter-2 Inhibitors and Mineralocorticoid Receptor Antagonists in Nondiabetic Kidney Disease. Kidney and Blood Pressure Research, 51(1), 409-420. https://doi.org/10.1159/000552201

Vancouver

Chen R, Zhang J, Chen J, Xie T, Xu Y, Hu Z, et al. Divergent Renal Benefits of Sodium-Glucose Cotransporter-2 Inhibitors and Mineralocorticoid Receptor Antagonists in Nondiabetic Kidney Disease. Kidney and Blood Pressure Research. 2026;51(1):409-420. doi:10.1159/000552201

BibTeX
@article{Chen2026,
  author = {Chen, Rulong and Zhang, Jinxin and Chen, Jiating and Xie, Tingfei and Xu, Yunpeng and Hu, Zhaoyong and Chen, Jihong},
  title = {Divergent Renal Benefits of Sodium-Glucose Cotransporter-2 Inhibitors and Mineralocorticoid Receptor Antagonists in Nondiabetic Kidney Disease},
  journal = {Kidney and Blood Pressure Research},
  year = {2026},
  volume = {51},
  number = {1},
  pages = {409--420},
  doi = {10.1159/000552201}
}
Kostenlos starten →